Figure 3.

Kaplan-Meier plots of disease-free (A and B) and overall (C and D) survival in primary resected Barrett's cancer patients according to CD45RO+ tumor infiltrating lymphocytes (TILs) and lymph node status. (A and C) Survival rates in patients without regional lymph node metastases. (B and D) Survival rates in patients with presence of regional lymph node metastasis. In each cohort high and low TIL densities were plotted according to the corresponding cut-off values. Blue lines indicate patients with tumors containing high CD45RO+ levels, red lines indicate patients whose tumors had low densities of CD45RO+. P values are calculated by log-rank tests. The 5-year disease-free survival (DFS) rate in the group of the patients without lymph node metastases was 69.4% for high CD45RO+ levels compared to 16.7% for patients with low levels of CD45RO+ levels (overall survival (OS): 69.9% versus 41.7%). In the group of the patients with lymph node metastases the 5-year DFS rate was 13.1% for patients with high densities of CD45RO+ in contrast to a rate of 15.6% for patients low densities of CD45RO+ (OS: 18.1% versus 15.3%).

Rauser et al. BMC Cancer 2010 10:608   doi:10.1186/1471-2407-10-608
Download authors' original image